We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Ophthalmology |

Highlights FREE

JAMA Ophthalmol. 2014;132(5):517. doi:10.1001/jamaophthalmol.2013.5938.
Text Size: A A A
Published online


Individual variation in response and duration of anti–vascular endothelial growth factor (VEGF) therapy is seen among patients with neovascular age-related macular degeneration. To understand how identification of genetic markers might affect clinical response of anti-VEGF therapy, Hagstrom and colleagues evaluated the pharmacogenetic relationship between genotypes of single-nucleotide polymorphisms in the VEGF signaling pathway and response to treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Among 835 participants, no association was identified with any of the genotypes or with the number of risk alleles. This study provides evidence that no pharmacogenetic associations exist between the studied VEGF single-nucleotide polymorphisms and response to anti-VEGF therapy.

Journal Club

Because effective strategies for primary prevention are lacking for exfoliation glaucoma, Kang and colleagues examined the association between B vitamin intake and exfoliation glaucoma or suspected exfoliation glaucoma risk within the Nurses’ Health Study. The authors were unable to identify an increased risk of vitamin B6 or vitamin B12 intake for this outcome in pooled analyses (P = .52 and P = .99 for linear trend, respectively), although the data suggested a reduced risk with higher intake of folate, supporting a possible causal role of homocysteine in exfoliation glaucoma. The authors warned that the results should be interpreted cautiously and the associations could be interpreted as hypothesis generating and not as proof of a cause and effect relationship.

Although electronic health record (EHR) systems have potential benefits, such as improved safety and quality of care, not all ophthalmology practices, including activities within the operating room (OR), have adopted these systems. Sanders and colleagues determined the impact of an EHR OR management system on intraoperative nursing documentation time, surgical volume, and staffing requirements. Among 13 ophthalmic OR nurses and 25 surgeons at an academic medical center, there was a worsening in total percentage of operating time documenting (83%) early in the adoption of the EHR vs paper (41%; P < .001), which improved to baseline levels (46%, P = .28) with time. The authors concluded that it is possible to implement an EHR OR management system without serious negative impacts on surgical volume and staffing requirements.

Dermal injection of cosmetic fillers can lead to numerous complications, but irreversible blindness when such fillers are injected in the forehead has not been well documented. To highlight this potential complication of a common cosmetic procedure, Carle and colleagues described irreversible vision loss from a central retinal artery occlusion occurring shortly after cosmetic facial enhancement in 3 patients. While cosmetic facial fillers are not approved by the Food and Drug Administration for use in the forehead, off-label use is reported to be common. The authors hypothesized that the filler presumably enters the central retinal artery via the rich external-internal carotid anastomoses and becomes embedded in the retinal tissues, potentially leading to irreversible and severe vision loss. Physicians performing cosmetic enhancement procedures involving facial fillers need to be aware of this potential complication.





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.